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Background: Malaria remains a major human health problem, with no licensed vaccine currently available. Malaria
infections initiate when infectious Plasmodium sporozoites are transmitted by Anopheline mosquitoes during their
blood meal. Investigations of the malaria sporozoite are, therefore, of clear medical importance. However,
sporozoites can only be produced in and isolated from mosquitoes, and their isolation results in large amounts of
accompanying mosquito debris and contaminating microbes.
Methods: Here is described a discontinuous density gradient purification method for Plasmodium sporozoites that
maintains parasite infectivity in vitro and in vivo and greatly reduces mosquito and microbial contaminants.
Results: This method provides clear advantages over previous approaches: it is rapid, requires no serum
components, and can be scaled to purify >107 sporozoites with minimal operator involvement. Moreover, it can be
effectively applied to both human (Plasmodium falciparum, Plasmodium vivax) and rodent (Plasmodium yoelii)
infective species with excellent recovery rates.
Conclusions: This novel method effectively purifies viable malaria sporozoites by greatly reducing contaminating
mosquito debris and microbial burdens associated with parasite isolation. Large-scale preparations of purified
sporozoites will allow for enhanced in vitro infections, proteomics, and biochemical characterizations. In conjunction
with aseptic mosquito rearing techniques, this purification technique will also support production of live attenuated
sporozoites for vaccination.
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Plasmodium species, the aetiological agents of malaria,
cycle between a mosquito vector and vertebrate host to
complete its life cycle. Mammals become infected with
malaria parasites when bitten by an infected Anopheles
mosquito, which deposits the sporozoite form of the
parasite into the host's skin (reviewed in [1]). Sporozoites
then actively seek the host vasculature and upon invading
it, passively migrate to the liver where they ultimately in-
fect a hepatocyte and replicate within it. This liver stage
of development (which lasts two days for rodent-
infective species or six to eight days for human-infective* Correspondence: Scott.Lindner@SeattleBioMed.org
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reproduction in any medium, provided the orspecies) results in the release of tens of thousands of red
blood cell-infectious exoerythrocytic merozoites. These
merozoites then initiate the blood stage of malaria infec-
tion that is associated with all clinical symptoms of the
disease.
The characterization of sporozoite infectivity has often
been limited by the presence of bacteria and yeast. Be-
cause of these contaminating microbes, the duration of
many in vitro infections of permissive hepatocytes is
often limited to only a few days. In addition, immuno-
compromised mice with humanized livers have recently
been developed to provide an in vivo model of liver stage
infections for both Plasmodium falciparum and Plasmo-
dium vivax ([2,3], Mikolajczak et al., personal communi-
cation). Infections of these mice with large numbers of
unpurified sporozoites can also systemically introduceal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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impact the health of these mice and affect the innate im-
mune response against the parasite during the 6–8 day
liver stage infection. These contaminants can similarly
confound investigations of basic immunological responses
of non-humanized mice against rodent malaria, as well.
Biochemical studies of sporozoites have also been
hampered by relatively large amounts of residual mos-
quito debris compared to the parasite mass. For in-
stance, proteomic studies of various Plasmodium species
have used unpurified sporozoites and this has resulted in
the identification of only a limited number of parasite-
specific peptide hits, presumably due to the large num-
ber of contaminating mosquito-derived peptides [4-6].
Substantial reduction of mosquito proteins would sub-
stantially help such characterizations.
A previously published method of sporozoite purifica-
tion requires that the parasites be first coated with bovine
serum albumin (BSA) and then passed through ion ex-
change resin [7]. While this described procedure produces
well-purified sporozoites, the fraction of sporozoites
recovered is routinely low (30-40%) even with sporozoites
obtained from isolated salivary glands (Lindner S., unpub-
lished results). Moreover, this approach yields parasites
coated with BSA, which is known to induce sporozoite
apical organelle secretion and motility [8,9]. Another
sporozoite purification method that employs BSA utilizes
a discontinuous density gradient composed of diatrozoate
sodium/Hypaque and several lengthy, high speed spins to
purify sporozoites [10]. When injected into mice, these
sporozoite preparations resulted in the death of significant
numbers of the mice due to an immune response to BSA
[11]. A revised protocol from the same authors that
employed mouse serum in lieu of BSA did curtail mouse
death, but did not reduce contaminating microbial
burdens (ibid).
Ideally, an effective malaria vaccine will confer sterile
protection prior to the onset of symptoms. The most
promising subunit vaccine candidate, RTS,S, is currently
in Phase 3 trials by GlaxoSmithKline but has shown only
partial protection from subsequent infections [12]. Re-
cent efforts have also focused on developing malaria vac-
cines comprised of live sporozoites attenuated by
irradiation or genetic disruption, including the first trial
testing syringe delivery of irradiated sporozoites [13-16].
These attenuated parasites are able to productively infect
hepatocytes, but arrest at specific points within the liver
stage of parasite development [17]. Interestingly, genetic-
ally attenuated parasites that arrest as late liver stage
parasites (e.g. pyfab b/f- parasites) provide greater and
broader CD8+ T-cell responses and higher levels of pro-
tection than do radiation attenuated parasites or early
arresting genetically attenuated parasites (ibid). Further
studies and large-scale implementation of these vaccinecandidates would greatly benefit from the production of
large numbers of sporozoites that have been purified
away from mosquito-derived contaminants to facilitate
their characterization and deployment.
To address all of the above problems, herein is
described a discontinuous density gradient purification
method that employs a dense layer composed of Accu-
denz dissolved in water. This strategy effectively removes
mosquito debris and hemocoel lipids, does not require
BSA or serum, greatly reduces bacterial contamination,
and eliminates yeast contamination. Moreover, this ap-
proach is applicable across all species of Plasmodium
tested, including rodent-infective Plasmodium yoelii and
human-infective P. falciparum and P. vivax sporozoites.
Importantly, this method is scalable, as >107 sporozoites
can be routinely purified in a single gradient with excel-
lent recovery rates. Lastly, this method is validated by
demonstrating that these purified sporozoites are fully
infectious in standard in vitro and/or in vivo infectivity
assays for all three species. Taken together, this method
provides a means to rapidly purify Plasmodium sporo-
zoites for both basic research and vaccine production
applications.
Methods
Accudenz column purification method
A 17% w/v solution of Accudenz (Accurate Chemical
#AN7050) dissolved in distilled deionized water (ddH2O,
Mediatech #25-055-CM) was filter sterilized and stored
at 4°C. A 3 ml Accudenz cushion was loaded in a 15 ml
conical tube and the dissected sporozoite mixture (up to
1 ml) was gently layered on top of the cushion. The col-
umn was spun at 2,500 g at room temperature for 20
minutes (no brake) and the interface (±) was transferred
to a new, clean microcentrifuge tube and spun at top
speed in a microcentrifuge for three minutes. The super-
natant was aspirated and the pelleted sporozoites were
resuspended in RPMI 1640 or Schneider’s insect medium
and counted in a haemocytometer. Three or more bio-
logical replicates of all tested species of Plasmodium spor-
ozoites (Plasmodium yoelii, P. falciparum, P. vivax) were
tested to confirm sporozoite recovery.
Plasmodium yoelii sporozoite production
Six-to-eight week old female Swiss Webster (“SW”) mice
from Harlan (Indianapolis, IN) were used for production
of wild-type P. yoelii 17XNL (“Py17XNL”, a non-lethal
strain) blood stage parasites. Animal handling was con-
ducted according to Institutional Animal Care and Use
Committee approved protocols at the Seattle Biomedical
Research Institute. Py17XNL parasites were cycled be-
tween SW mice and Anopheles stephensi mosquitoes
that had been reared by standard methods (as described
in Methods in Anopheles Research available at www.
Kennedy et al. Malaria Journal 2012, 11:421 Page 3 of 10
http://www.malariajournal.com/content/11/1/421mr4.org). Infected mosquitoes were maintained on an
8% w/v dextrose solution in 0.05% w/v PABA water at
24°C and 70% humidity in 12 hour light/dark cycles.
Mosquitoes were collected into sterile 70% v/v ethanol
in ddH2O, rinsed in sterile ddH2O and finally washed in
sterile 1xPBS. Salivary glands were individually isolated
by microdissection in sterile RPMI media 14–16 days
post-blood meal from batches of 50–75 mosquitoes, and
were placed in a microfuge tube containing sterile RPMI
media. Sporozoites were then released by three rounds
of manual grinding of salivary glands (50 grinds per
round), with glands re-pelleted at 100 g for 1 minute be-
tween rounds. The sporozoite-containing mixture was
applied to the gradient as described above.Plasmodium falciparum sporozoite production
In vitro P. falciparum (NF54 strain) cultures were main-
tained in O+ erythrocytes grown in RPMI 1640 (25 mM
HEPES, 2 mM L-glutamine) supplemented with 50 μm
hypoxanthine and 10% A+ human serum in an atmosphere
of 5% CO2, 5% O2, and 90% N2. Gametocyte cultures
were initiated at 5% haematocrit and 0.8-1% parasitaemia
(mixed stages) and maintained for up to 17 days with
daily media changes.
Non-bloodfed adult female An. stephensi mosquitoes
three to seven days post-emergence were collected into
mesh-topped, wax-lined pots each containing up to 300
mosquitoes. Gametocyte cultures were quickly spun
down and the pelleted infected erythrocytes were diluted
to 40% haematocrit with fresh A+ human serum and O+
erythrocytes. Mosquitoes were allowed to feed upon
these cultures through Parafilm for up to 20 minutes.
Following blood feeding, mosquitoes were maintained
for up to 19 days at 27°C, 75% humidity and were pro-
vided with an 8% w/v dextrose solution in 0.05% w/v
PABA water. Salivary gland sporozoites were isolated as
described above by microdissection 14–19 days post-
blood meal.Plasmodium vivax sporozoite production
Blood samples from P. vivax-infected patients were col-
lected at the Malaria Clinics (Kanchanaburi province,
Thailand) in accordance with an approved human re-
search protocol (protocol# TMEC 11–033, Faculty of
Tropical Medicine, Mahidol University). Infected blood
was heparinized and fed to five to seven-day old female
Anopheles dirus mosquitoes using a membrane-feeding
device [18]. Infected mosquitoes were maintained at
26°C, 75% humidity and were provided with a 10% w/v
dextrose solution in water. Salivary gland sporozoites
were isolated by microdissection as described above
15–18 days post-blood meal, but in batches of five
mosquitoes at a time.Measurement of the reduction of bacterial contaminants
Plasmodium yoelii salivary gland sporozoites were dis-
sected from three independent mosquito cages and were
resuspended at 2×105 sporozoites/1ml RPMI 1640
media. Sporozoites were either left untreated, or were
incubated with 200 IU penicillin / 200 mg/ml strepto-
mycin (Cellgro, Cat#30-002-CI) for 20 minutes at room
temperature. Sporozoites from both conditions were
then either left unpurified, or purified as described
above. Sporozoites were pelleted, washed in RPMI 1640
to remove residual antibiotics, counted on a haemocyt-
ometer, serially diluted to 25000, 2500, 250, and 25 spor-
ozoites in 100 μl RPMI 1640 and were plated on LB-agar
plates. Plates were incubated at 37°C for 12–14 hours
and colony-forming units per sporozoite plated were
determined by manual counting.
Assessment of in vivo P. yoelii sporozoite infectivity
Plasmodium yoelii salivary gland sporozoites were iso-
lated from mosquito salivary glands, and 103 or 104
sporozoites were injected intravenously (“iv”) into the
tail vein of SW mice. The time to blood stage patency
(defined as >1 infected RBCs / 20,000 RBCs) was deter-
mined microscopically by Giemsa-stained thin blood
smears. A one-day delay in the time to blood stage pa-
tency correlates with a 90% reduction in sporozoite in-
fectivity [19]. Two biological replicates were measured
for each condition.
Assessment of in vitro P. vivax and P. falciparum
sporozoite infectivity
HC-04, a human hepatocyte cell line, was used to pro-
duce liver stage infections [20]. Cells (2.5×104) were
seeded in each well of a 8-well chamber slides (LabTek,
Campbell, CA) and incubated at 37°C with a complete
medium (P. vivax: equal volumes of MEM and Ham’s
F12 (Gibco BRL); P. falciparum: DMEM) supplemen-
ted with 10% foetal bovine serum, 100 U/ml penicil-
lin, and 100 μg/ml streptomycin. At 24 h, the medium
was aspirated and replaced with 2×104 purified sporo-
zoites in 250 μl of invasion medium (P. vivax: MEM:
Ham’s F12 supplemented with 10% human AB serum,
100 U/ml penicillin, 100 μg/ml streptomycin, and
0.25 μg/ml fungizone; P. falciparum: complete media
as above). After a four hour incubation, the invasion
medium was aspirated and 300 μl of fresh complete
medium (as above) was added to the infected hepato-
cytes. The culture was maintained for up to four days
with daily media changes prior to visualization by an
IFA (see below).
Assessment of in vivo P. falciparum sporozoite infectivity
Female FRG NOD huHep mice with human chimeric livers
(Yecuris Corp.) were infected with purified P. falciparum
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described [3]. Six and seven days post-infection, mice were
injected intravenously with 400 μl of packed O+ human
RBCs. Mice were sacrificed two hours after the second
RBC injection, and the blood was collected by cardiac
puncture and placed into in vitro culture under standard
conditions. Additionally, livers were simultaneously har-
vested and processed for IFA (see below).Indirect immunofluorescence assay (IFA)
Salivary gland sporozoites, in vitro and in vivo infected
hepatocytes were processed for IFA essentially as
described [21]. All sample types were stained at room
temperature with phalloidin or the following appropri-
ately diluted primary antibodies (rabbit anti-human
fumaryl acetoacetate hydrolase (FAH, Yecuris), mouse
anti-PfMSP1 (MR4), mouse anti-PfCSP (Clone 2A10),
mouse anti-PvCSP210, mouse anti-PvCSP247, mouse
anti-PbHsp70 (Clone 4C9) [22], Alexa Fluor- or FITC-
conjugated secondary antibodies specific to mouse or
rabbit IgG (Alexa Fluor 488, 594, Invitrogen; Dako),
and 40,6-diamidino-2-phenylindole (DAPI). Samples
were covered with VectaShield (Vector Laboratories)
and sealed under a coverglass slip. Fluorescent and
DIC images were acquired using a DeltaVision Spectris
RT microscope (Applied Precision) using a 40× or
100× oil objective and were deconvolved using the
softWoRx software package, except for P. vivax liver
stage parasites, which were acquired using a Nikon
ECLIPSE 80i microscope with NIS-Elements F 3.0
software.Flow cytometric quantification of sporozoite invasion
Infection of HC-04 hepatocytes by P. falciparum sporo-
zoites was measured as described previously [23]. Briefly,
4×105 HC-04 cells were plated in each well of a 24-well
plate one day prior to mock infection with dissection
media or infection with 105 P. falciparum NF54 strain
purified or unpurified sporozoites. Infection was allowed
to proceed for 90 minutes, at which point hepatocytes
were trypsinized, extensively washed, fixed, and permea-
bilized. Hepatocytes were blocked and then stained with
an Alexa-Fluor 488-conjugated anti-PfCSP (2A10) to de-
tect CSP-positive hepatocytes with a LSRII flow cytometer
(Becton Dickinson) and FlowJo Software. Samples were
normalized to the percent of hepatocytes infected by un-
purified sporozoites (set at 100%).Statistics
A measurement of the statistical significance of sporozo-
ite infectivity in vitro was conducted by a standard stu-
dent’s t-test.Results
Determination of critical purification parameters
After sporozoite isolation from mosquito midguts or sal-
ivary glands, many sporozoite investigations are then
hampered by excessive amounts of mosquito debris,
microbes such as bacteria and yeast, or both. It would,
therefore, be beneficial to devise a purification method
to simultaneously solve both problems that would re-
quire minimal operator involvement (<5 minutes), be
simple (one step), be rapid (20 minutes) and be scalable
(able to purify millions of sporozoites simultaneously).
To this end, several commercially available chemicals
commonly used to create density gradients were
assessed for their ability to purify sporozoites, and
Accudenz-based gradients were identified as the top per-
former. Gradients that used Accudenz as the dense layer
consistently produced the highest recovery of purified
sporozoites from the bilayer interface (P. yoelii: 80.4% ±
11.6; P. falciparum 81.3% ± 5.74; P. vivax 61.9 ± 6.86),
and have been used to successfully purify as few as 105
sporozoites to over 2×107 sporozoites in a single gradient
with comparable sporozoite recoveries (Additional file 1).
The Accudenz gradient also performed well in removing
both mosquito debris (which forms a pellet at the base of
the tube) and lipids (which float to the top of the gradient)
(Figure 1A). Microscopically, the purity of these sporozo-
ite samples was excellent as well, with little to no con-
taminating material visibly remaining after centrifugation
(Figure 1B).
During the optimization of this purification method,
three major parameters were identified that affected
sporozoite recovery: the solvent used to produce the
Accudenz cushion, the final concentration of Accudenz
in the dense layer, and the relative centrifugal force ap-
plied to the gradient. Plasmodium falciparum sporo-
zoites were loaded onto cushions of Accudenz dissolved
in either 2× phosphate buffer saline (PBS), 1×PBS,
0.5×PBS or distilled, deionized water (ddH2O) and spun
at 2,500 g for 20 minutes at room temperature (RT). A
strong, dose-dependent negative effect on the percent
recovery of sporozoites was observed with increasing
concentrations of solutes present in PBS. In contrast,
using ddH2O as the solvent allowed for consistently high
percentage recoveries of sporozoites, and was used for
all subsequent experiments (Additional file 2). The opti-
mal concentration of Accudenz for use in the dense
layer (17%) was determined by testing a range of con-
centrations (5, 10, 17, 25% w/v in ddH2O) with P. falcip-
arum sporozoites (Additional file 3).
Additionally, using both sporozoite recovery and
amounts of residual mosquito debris as metrics, various
relative centrifugal forces (1,500 g, 2,000 g, 2,500 g, 3,000 g)
were tested upon the gradient and it was determined
that optimal recovery and purification was obtained at
Figure 1 Accudenz density gradient purification of Plasmodium sporozoites. A. Photographs of a bilayer discontinuous Accudenz density
gradient overlayed with P. yoelii sporozoites in RPMI before and after centrifugation. Mosquito debris pellets to the bottom of the gradient,
mosquito lipids float to the top of the gradient, and sporozoites accumulate at the bilayer interface. B. Representative DIC images of unpurified
and purified sporozoites before and after centrifugation show a significant reduction in mosquito material. Scale bar is 5 microns.
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for sporozoite purification employ a 17% w/v Accudenz
in ddH2O cushion under the dissected sporozoite mix-
ture (in either RPMI 1640 or Schneider’s Medium), spun
at 2,500 g for 20 minutes at room temperature.
Reduction/elimination of contaminating microbial
burdens
Using these optimized purification conditions, it was
determined if this method would significantly reduce the
amounts of contaminating bacteria and yeast remaining
with the purified sporozoites. To this end, P. yoelii saliv-
ary gland sporozoites were either left unpurified or were
purified over an Accudenz cushion as described. Add-
itionally, to test if pre-treatment of the sporozoites with
antibiotics would further reduce the microbial burden,
samples were incubated with penicillin/streptomycin or
left untreated. Serial dilutions of sporozoites from each
of these four conditions were plated on LB agar plates,
the number of colony forming units (CFUs) per sporozo-
ite was counted (Table 1). No significant reduction in
CFUs was achieved by pre-treatment of sporozoites with
antibiotics alone. In contrast, Accudenz purificationTable 1 Measurements of the reduction of bacterial contamin
Accudenz of P. yoelii sporozoites
- - +
- + -
Replicate 1 0.84 0.68 0.017 (98.0
Replicate 2 1.2 2.1 0.040 (96.6
Replicate 3 1.0 1.6 0.022 (97.8
Salivary gland sporozoites were resuspended in RPMI 1640, left untreated or treated
Accudenz discontinuous gradient. Sporozoites were pelleted and washed in RPMI 1
forming units per sporozoite are listed for three biological replicates. Percent reduc
unpurified sporozoites not treated with penicillin/streptomycin are listed in parenthgreatly reduced bacterial contamination (97.5% + 0.757)
associated with sporozoites, which was further affected
by treatment with penicillin and streptomycin (99.0% +
0.252). In confirmation of this, an equal number of un-
purified or purified P. yoelii (105), P. falciparum (105), or
P. vivax (2×104) sporozoites were inoculated into
complete DMEM or RPMI 1640 media in independent
wells of 6-well tissue culture plates at 37°C with 5%
CO2. All wells containing unpurified sporozoites became
overgrown (visible by eye and/or microscopically) with
bacteria (within 1–2 days) or yeast (within 4 days, data
not shown), whereas wells containing purified sporo-
zoites routinely remained free from contamination for at
least 1 week.
Purified P. yoelii sporozoites are fully infectious to mice
Having demonstrated that this method readily produces
highly purified Plasmodium sporozoites, it was critical to
next determine if these sporozoites remained infectious.
This was first assessed by testing for any significant loss
of infectivity with the rodent-infective P. yoelii malaria
parasite, as this can be easily measured by the presence






with penicillin/streptomycin, and were left unpurified or were purified on an
640, and then serially diluted and plated on LB-agar plates. Total colony
tions of residual bacterial burdens for purified sporozoites compared to
esis.
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venous (iv) injection of salivary gland sporozoites. Using
naïve outbred Swiss Webster (SW) mice, 103 or 104 un-
purified or purified sporozoites were iv injected and the
time to blood stage patency (defined as >1 Giemsa-posi-
tive, infected RBC per 20,000 RBCs on a thin blood
smear) was measured. All mice infected with either puri-
fied or unpurified sporozoites developed blood stage pa-
tency at the same time point after infection (depending
on the initial dose), indicating that no detectable loss of
sporozoite infectivity (e.g. less than 10-fold) was pro-
duced by this purification method nor by sporozoite
pre-treatment with penicillin/streptomycin (Table 2).
Purified P. falciparum sporozoites have no loss of
infectivity in vitro
As purification of sporozoites over an Accudenz gradient
significantly reduced the contaminating microbial bur-
den found associated with sporozoites, it would also be
important to determine if there was any effect upon the
infectivity of P. falciparum sporozoites for hepatocytes
in vitro. The human hepatocarcinoma cell line HC-04
was mock infected without sporozoites, or incubated
with unpurified or purified sporozoites. Observations of
infected hepatocytes by an indirect immunofluorescence
assay (IFA) one day post-infection demonstrated no sig-
nificant difference in parasite morphology with purified
or unpurified sporozoites (Figure 2A). Moreover, while
wells incubated with unpurified sporozoites readily be-
came contaminated within two to three days, wells that
received purified sporozoites remained contamination-
free for the complete length of the assay (typically at
least one week). Additionally, the fraction of infected
hepatocytes was measured shortly after sporozoiteTable 2 Measurements of the time to blood stage
patency indicate that there is no loss of infectivity with
purified P. yoelii sporozoites






Unpurified 1 10,000 5 5 (3d)
2 10,000 5 5 (3d)
1 1,000 5 5 (4d)
2 1,000 5 5 (4d)
Purified 1 10,000 5 5 (3d)
2 10,000 5 5 (3d)
1 1,000 5 5 (4d)
2 1,000 5 5 (4d)
Salivary gland sporozoites were isolated from mosquitoes at 14d post-blood
meal and injected intravenously into groups of five naïve Swiss Webster mice
in duplicate. Time to blood stage patency (defined as >1 parasite per 20,000
RBCs) was determined microscopically by daily Giemsa-stained thin blood
smears, and was identical for sporozoites pretreated with antibiotics or for
those left untreated.infection (90 minutes) by using a recently published flow
cytometric assay [23]. This assay allows precise quantifi-
cations of infection by analysing large numbers of cells
(105) for the presence of the most abundant sporozoite
protein, circumsporozoite protein (CSP).
Representative plots (Figure 2B) and a normalized
graph of duplicate biological replicates (Figure 2C) of
mock infected cells, or cells infected with unpurified or
purified sporozoites indicate that no significant differ-
ence (measured by a student’s t-test) in P. falciparum
sporozoite infectivity exists between purified and unpuri-
fied parasites in vitro.
Purified P. vivax sporozoites retain infectivity in vitro
This purification technique was also tested to determine
if it could be extended to P. vivax sporozoites, another
major human-infective malaria species. Salivary gland
sporozoites (both CSP210 and CSP247 parasite types
[24]) were dissected from infected Anopheles dirus mos-
quitoes by standard methods, and were purified using
standard optimized conditions. Consistently 55-69% of
the input sporozoites were recovered with a comparable
elimination of mosquito debris as with other species.
Both the CSP210 and CSP247 types of purified P. vivax
sporozoites were examined by IFA and found to retain
normal morphology and antibody staining patterns
(Figure 2D). The ability of purified and unpurified sporo-
zoites to productively infect HC-04 hepatocytes in vitro
was also tested. Mixed populations of CSP210 and
CSP247 types of P. vivax sporozoites were allowed to in-
fect and develop for four days, and were then observed
by IFA. In both conditions, a comparable number of ap-
propriately developing liver stage parasites were detected
(94.2% ± 16.6, Figure 2E). This indicates that as with P.
yoelii and P. falciparum, purified P. vivax sporozoites re-
tain their infectivity for hepatocytes. Moreover, it was
also observed that Accudenz purification routinely
removed all traces of yeast contamination from the spor-
ozoites, whereas unpurified sporozoites lead to the well
becoming overgrown with yeast within 4 days. This
sporozoite purification method should now enable long-
term in vitro cultures, especially for the study of hypno-
zoites, to be routinely maintained contamination-free.
Purified P. falciparum sporozoites productively complete
liver stage development in a humanized mouse model
and transition to a sustainable blood stage infection
It has recently been shown that the FRG NOD huHep
mouse, a human-liver chimeric mouse, can support
complete P. falciparum liver stage development [3].
Additionally, these mice were competent to allow a liver
stage to blood stage transition [3]. Since the FRG NOD
huHep mouse is immunocompromised, it could be sur-
mised that injection of these mice with purified sporozoites
Figure 2 (See legend on next page.)
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Figure 2 Purified P. falciparum and P. vivax sporozoites remain infectious in vitro. A. HC-04 cells were infected with unpurified or purified
P. falciparum sporozoites for 24 hours and were then subjected to an IFA (green: anti-PfCSP (2A10), blue: DAPI). Scale bar is 10 microns. B.
Representative plots of sporozoite infectivity are provided from flow cytometric measurements of anti-Pf CSP antibody staining of HC-04 cells C.
A graphical representation of two biological replicates of infections from (B) demonstrates that there is no infectivity defect of purified
sporozoites. D. Purified P. vivax sporozoites were observed by IFA (green: anti-PvCSP 210 or anti-PvCSP247, blue: DAPI). No gross differences in
parasite morphology were detected. Scale bar is 5 microns. E. HC-04 cells were infected with unpurified and purified P. vivax sporozoites for four
days and developing liver stage parasites were observed by IFA (green: anti-PbHsp70, red: Phalloidin, blue: DAPI). No gross differences in parasite
morphology were detected. Scale bar is 5 microns.
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which could affect the health of the mice and possibly liver
stage development. Therefore, two FRG NOD huHep mice
were injected intravenously with 3 × 106 purified P. falcip-
arum sporozoites. Mice were injected with human red
blood cells as previously described and the mice were
euthanized seven days after sporozoite infection [3]. The
blood removed from the mice was transitioned into a P.
falciparum asexual culture and indeed, a healthy in vitro
asexual culture of transitioned P. falciparum blood stages
was achieved. The livers were also removed from the
euthanized mice, fixed and subjected to an IFA as previ-
ously described [25]. Using antibodies to parasite mero-
zoite surface protein 1 (MSP1) and human fumaryl
acetoacetate hydrolase (FAH) (present only in the human
hepatocytes within the FRG NOD huHep mouse liver), as
expected, mature liver stages were observed to be present
in the livers of the inoculated mice (Figure 3). Thus, the
purified P. falciparum sporozoites appear to behave no dif-
ferently to the unpurified P. falciparum sporozoite in this
in vivo assay of liver stage development and ex vivo/in vitro
assay of liver stage to blood stage transition.
Discussion
This work describes and demonstrates that an Accudenz
density gradient purification method of Plasmodium
sporozoites produces parasites that remain viable andFigure 3 Purified P. falciparum sporozoites remain infectious to a hum
falciparum parasites are shown using antibodies to human FAH (green), PfM
sporozoites are able to fully progress through liver stage development. Scainfective. A discontinuous gradient approach was favored
over using a continuous gradient, as the former also acts
to localize and concentrate sporozoites at the interface of
the light and dense layers. This approach thus removes
the requirement to collect and assess multiple samples for
the presence of sporozoites, which is needed when using
continuous gradients as sporozoites distribute throughout
a larger portion of the gradient [26,27]. Moreover, this
rapid and technically simple method successfully
removes mosquito debris and lipids, as well as contam-
inating bacterial and fungal contaminants. Importantly,
this is accomplished in the absence of serum or any
serum components, which are known to induce sporo-
zoite secretion and can cause immune responses in
mice. Lastly, this approach was successfully scaled up
and allowed the recovery of >107 sporozoites from a
single density gradient. This purification method was
validated for both rodent-infective and human-infective
malaria species, as purified sporozoites perform identically
to unpurified sporozoites by all in vitro and in vivo assays
used to date.
Of special interest was the implementation of these
purified sporozoites with humanized mouse models. In-
jection of purified sporozoites into the immunocom-
promised FRG NOD huHep mouse could be most
beneficial due to the removal of contaminating bacteria
and fungi which could cause inflammatory responses inanized mouse. Two representative IFA panels of late liver stage P.
SP1 (red) or with DAPI (blue). These images indicate that purified
le bar is 10 microns.
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their death. Inflammation could cause the death of P.
falciparum liver stage parasites early after infection. If
comparative studies were to be made on liver stage in-
fectivity in the FRG huHep mouse model, purification of
sporozoites would be vital to exclude the differing levels
of microbial burden between sporozoite samples.
Also, because this method completely eliminated yeast
contamination of P. vivax sporozoites, long-term in vitro
assays should no longer be impacted by this contamin-
ant. This is of particular interest for investigations of
liver stage development of P. vivax. Not only will this
enable easier characterization of the actively growing
forms of the liver stage parasite, which take approxi-
mately 8 days to fully develop in vivo, but perhaps also
studies of the poorly characterized “dormant forms”
(termed hypnozoites) of the parasite. Hypnozoites are a
major reservoir of viable parasites in infected indivi-
duals, which can persist for years and likely substantially
hinder efforts to eradicate the disease.
In addition to the infectivity assays described here, it is
anticipated that this purification method will greatly fa-
cilitate biochemical and molecular biological investiga-
tions that were hindered by the high amounts of
microbial contamination and/or mosquito debris. For in-
stance, previously reported proteomic efforts of sporo-
zoites have been limited by contaminating mosquito
proteins, which required large numbers of mass spec-
trometric runs to identify hundreds of parasite pro-
teins. In contrast, recent proteomic efforts with
purified sporozoites have overcome this limitation,
producing the most comprehensive proteomes of this
stage (~1,900-2,000 proteins), with >86% of proteins
identified by multiple unique peptide hits (Lindner and
Swearingen et al. submitted). Further investigations of
sporozoite biology will no doubt benefit from these
approaches as well.
Lastly, with the development of live attenuated sporo-
zoites as potential malaria vaccines come several tech-
nical hurdles should a lead candidate be identified in
clinical trials for large-scale implementation. One such
hurdle is the effective removal of contaminating mos-
quito debris associated with the sporozoites. This density
gradient purification method should meet several of
the metrics required for this process (e.g. purity, in-
fectivity, scalability), and may prove useful to stream-
line these efforts. When combined with aseptic
mosquito rearing techniques, this method could
make syringe administration of live attenuated sporo-
zoite immunizations practical. All told, this novel,
cross-species purification method holds great prom-
ise for accelerating both basic research of sporozoite
biology and translational efforts to use the sporozoite
medically.Conclusions
Described in this study is a discontinuous density gradi-
ent method that rapidly and effectively purifies malaria
sporozoites by greatly reducing contaminating mosquito
debris and microbial burdens associated with parasite
isolation. Moreover, the viability of these sporozoites
was confirmed, and the application of this approach to
commonly used in vitro and in vivo assays was demon-
strated. Large-scale preparations of sporozoites purified
by this approach will allow for enhanced in vitro infec-
tions, proteomics, and biochemical characterizations. Fi-
nally, this purification method, in conjunction with
aseptic mosquito rearing techniques, will support pro-
duction of live attenuated sporozoites that will be suit-
able for vaccination.
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